Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that the Company has engaged Mr. Hamish Sutherland as a strategic business consultant to work with Canntab and develop additional sales and distribution channels for the extensive suite of Canntab's products and to assist Canntab in reaching strategic partnerships in the Cannabis industry with a view to enhancing shareholder value.

Mr. Sutherland is a seasoned veteran of the legal cannabis industry in Canada, with over nine years' experience and a successful track record in the sector. His past achievements and contributions include holding the position of founding Chief Operating Officer of Bedrocan Canada Inc. (subsequently acquired by Tweed to form Canopy Growth Corporation), delivering over $750 million in investor value and overseeing the building and commissioning of two licensed facilities, including a 52,000 square foot state-of-the-art automated facility in suburban Toronto. Mr. Sutherland also serves as officer and director of various public and private cannabis companies in Canada, the United States and Australia, including Indiva Inc. (TSXV: NDVA), Mera Cannabis Corp., Altopa Inc. and Asterion Cannabis Inc. Mr. Sutherland holds an MBA from the Schulich School of Business at York University as well as a degree in Engineering Physics from McMaster University.

Mr. Sutherland's mandate is to maximize the potential of Canntab's assets, intellectual property, and operations with the primary objective of identifying and negotiating partnerships to assist Canntab in expanding its product offerings in Canada, United States, and other international jurisdictions. In addition, Mr. Sutherland will be working with his extensive network in the cannabis industry to explore M&A opportunities. This process has not been initiated because of receiving any offer and there are no assurances that any additional transactions will be undertaken.

"We are very pleased to have Hamish join our team. Mr. Sutherland's deep operational expertise in the cannabis industry specifically in the areas of finance, capital markets and corporate strategy will expand the skills matrix of the Canntab team, with the goal of generating one or more transactions to enhance shareholder value" said Larry Latowsky, CEO.

Engagement Details

Mr. Sutherland's engagement is initially for a four-month period, which can be extended on a month-to-month basis for an addition two months. Mr. Sutherland will receive $5,000 a month and has been issued 40,000 common shares of Canntab ("Canntab Shares"). In addition, Canntab has also granted 200,000 stock options (the "Options") to Mr. Sutherland exercisable at $0.50 per Share for a period of 4 years. In addition, Mr. Sutherland will be entitled to receive finder's fees for any strategic initiative completed during his mandate or introduced to the Company by him.